Aduhelm

Risk for amyloid related imaging abnormalities (ARIA), either with edema (ARIA-E), or with hemosiderin deposition (ARIA-H). Consider testing for ApoE ε4 carrier status to determine the risk for ARIA prior to treatment initiation. Risk for intracerebral hemorrhage: prior intracerebral hemorrhage >1cm in diameter, >4 microhemorrhages, superficial siderosis, history of diffuse white matter disease. Perform clinical evaluation if ARIA symptoms occur (esp during titration), including MRI testing if indicated. Obtain recent MRI (within 1yr) prior to initiation, and prior to 5^th, 7^th, 9^th, and 12^th infusions. Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.